Clinical trials: Demyelinating Disease
Progressive Multifocal Leukoencephalopathy
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML).
- Trial name
- NCT01211639
- Where
- 11 sites in United States, Germany
- Volunteers
- 24 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis
The main purpose of this study is to evaluate the safety and tolerability of the ocrelizumab subcutaneous (SC) test formulation in participants with multiple sclerosis (MS).
- Trial name
- OCARINA 3 (NCT07667322)
- Testing
- Ocrelizumab Co-formulated With rHuPH20
- Where
- 12 sites in United States, Brazil and 2 more
- Volunteers
- 75 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Chronic Inflammatory Demyelinating Polyneuropathy
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
The purpose of this Phase 3 study is to demonstrate the efficacy of claseprubart (DNTH103) as compared to placebo in participants with chronic inflammatory demyelinating polyneuropathy (CIDP).
- Trial name
- CAPTIVATE (NCT06858579)
- Testing
- Claseprubart
- Where
- 201 sites in United States, Argentina and 29 more
- Volunteers
- 256 people
- Sponsor
- Dianthus Therapeutics
Multiple Sclerosis
A Study Comparing the Effectiveness and Safety of Teriflunomide and Interferon Beta-1a in Patients With Relapsing Multiple Sclerosis
Primary objective was to assess the effectiveness evaluated by the time to failure of two doses of teriflunomide in comparison to interferon beta-1a in participants with relapsing Multiple Sclerosis [MS].
- Trial name
- TENERE (NCT00883337)
- Testing
- Interferon β-1a, Teriflunomide
- Where
- 54 sites in Belgium, Canada and 11 more
- Volunteers
- 324 people
- Sponsor
- Sanofi
Multiple Sclerosis
MSPT Device Usability Study
The primary objective of this feasibility study is to evaluate the functionality (e.g., as defined by the primary endpoints) of the fully integrated Multiple Sclerosis Performance Test (MSPT) device, when used by unsupervised…
- Trial name
- MSPT (NCT02664324)
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-remitting
Observational Study of Rebismart®2.0 + MSdialog™ in Subjects With Remitting Multiple Sclerosis (ADHERQOL)
This is a 24-month, observational, prospective, multinational, multicenter study to determine the relationship between the relapse (percentage of relapse free subjects) and adherence in subjects diagnosed with RRMS treated with…
- Trial name
- ADHERQOL (NCT02394782)
- Testing
- RebiSmart®2.0, MSdialog™
- Where
- Germany
- Volunteers
- 8 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Evaluation of an Altered Peptide Ligand (NBI-5788) in Patients With Relapsing Multiple Sclerosis (MS)
We are studying this investigational drug treatment, comparing it with placebo, to evaluate whether it is effective in reducing the number of MRI lesions with a minimum number of side effects.
- Trial name
- NCT00079495
- Testing
- NBI-5788
- Volunteers
- 150 people
- Sponsor
- Neurocrine Biosciences
Multiple Sclerosis
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
- Trial name
- ZENITH (NCT07224373)
- Testing
- AZD0120 - Regimen 1, AZD0120 - Regimen 2
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Multiple Sclerosis
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years.
- Trial name
- ENLIGHTEN (NCT04140305)
- Testing
- RPC-1063
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 188 people
- Sponsor
- Celgene
Mitochondrial Diseases, Drug Resistant Epilepsy
A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
This is a parallel-arm, double-blind, placebo-controlled study with a screening phase that includes a 28-day run-in phase to establish baseline seizure frequency, followed by a 24-week, randomized, placebo-controlled phase.
- Conditions
- Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome
- Trial name
- MIT-E (NCT04378075)
- Testing
- Vatiquinone
- Where
- 27 sites in United States, Canada and 7 more
- Volunteers
- 68 people
- Sponsor
- PTC Therapeutics
Relapsing-remitting Multiple Sclerosis
Safety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or Rebif
The purpose of this study is to compare the injection site reaction and injection site pain after subcutaneous administration of either Betaferon 250µg or Rebif 44µg using different autoinjectors.
- Trial name
- NCT00317941
- Testing
- Betaferon/Betaseron, Rebif
- Where
- 59 sites in France
- Volunteers
- 220 people
- Sponsor
- Bayer
Multiple Sclerosis (MS)
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Relapsing Forms of Multiple Sclerosis
The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with relapsing Multiple Sclerosis (RMS).
- Trial name
- NCT03737851
- Testing
- elezanumab
- Where
- 49 sites in United States, Canada
- Volunteers
- 208 people
- Sponsor
- AbbVie
Multiple Sclerosis
US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector
In this study researchers want to learn more about the medication usage behavior among multiple sclerosis (MS) patients treated with BETASERON using the myBETAapp.
- Trial name
- NCT04356339
- Testing
- Interferon-beta-1b (BETASERON, BAY 86-5046)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Bayer
Multiple Sclerosis
Exploratory Pilot Study on the Prolonged Use of the ABLE Exoskeleton in Multiple Sclerosis
The goal of this study is to explore the potential clinical benefits of the ABLE Exoskeleton as part of a rehabilitation program in people with multiple sclerosis.
- Trial name
- NCT06921551
- Testing
- ABLE Exoskeleton
- Where
- Spain
- Volunteers
- 19 people
- Sponsor
- ABLE Human Motion S.L.
Multiple Sclerosis
A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
The purpose of this study is to assess the imaging biomarkers, patient outcomes, safety, tolerability, and treatment satisfaction of ocrelizumab (OCR) combined with recombinant human hyaluronidase (rHuPH20) administered…
- Trial name
- OSSIA (NCT07609719)
- Testing
- OCR SC
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 100 people
- Sponsor
- Genentech, Inc.
Central Nervous System (CNS) Demyelinating Disease, Multiple Sclerosis
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants
The primary objective of this study is to assess the safety and tolerability of a single dose and multiple doses of BIIB033 administered to healthy adult Japanese participants.
- Trial name
- NCT02641041
- Testing
- BIIB033
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.
This observational multicentric study is planned to assess the tolerability of Rebif New Formulation in an Australian clinical setting by the incidence of injection site reactions (ISRs).
- Trial name
- ReNew (NCT01101776)
- Testing
- Interferon beta-1a (Rebif)
- Where
- 16 sites in Australia
- Volunteers
- 49 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
The purpose of this MAP Cohort Treatment Plan is to allow access to siponimod for eligible patients diagnosed with Secondary Progressive Multiple Sclerosis with active disease.
- Trial name
- NCT04540861
- Testing
- Siponimod
- Sponsor
- Novartis Pharmaceuticals
Spasticity, Multiple Sclerosis
A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.
The purpose of this study is to evaluate the efficacy, safety and tolerability of Sativex® in subjects diagnosed with MS and spasticity.
- Trial name
- NCT00711646
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 189 people
- Sponsor
- Jazz Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.